Article

ASCO '12 Abstract Dump: Cancer Stocks in Focus

Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.

_

(AVEO)

(EXEL_)

_

(ARRY)

Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Aveo Pharmaceuticals and Exelixis, and randomized phase II studies of drugs discovered by Array BioPharma.

Read the full story: http://hcp.lv/KlaVJ3

Source: The Street

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo